Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AVTX Avalo Therapeutics > Detailed Quotes

AVTX Avalo Therapeutics

Watchlist
5.460
+0.140+2.63%
Close 11/25 13:00 ET
High
5.460
Open
5.350
Turnover
3.36K
Low
5.350
Pre Close
5.320
Volume
620.00
Market Cap
51.40M
P/E(TTM)
Loss
52wk High
25.500
Shares
9.41M
P/E(Static)
Loss
52wk Low
2.423
Float Cap
18.04M
Bid/Ask %
33.33%
Historical High
91.799
Shs Float
3.30M
Volume Ratio
0.14
Historical Low
2.412
Dividend TTM
--
Div Yield TTM
--
P/B
-25.40
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.02%
Amplitude
2.07%
Avg Price
5.419
Lot Size
1
Float Cap
18.04M
Bid/Ask %
33.33%
Historical High
91.799
Shs Float
3.30M
Volume Ratio
0.14
Historical Low
2.412
Dividend TTM
--
P/B
-25.40
Dividend LFY
--
Turnover Ratio
0.02%
Amplitude
2.07%
Avg Price
5.419
Lot Size
1
Price Forecast

No Data

News

Comment

Sign in to post a comment

No comment yet

Company Overview More
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO: Dr. Garry A. Neil, M.D.
Market: NASDAQ
Listing Date: 11/13/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist